claim: repurposing of miglustat to form the coronavirus severe acquired respiratory syndrome sars-cov-2.
evidence_1: repurposing of miglustat to inhibit the coronavirus severe acquired respiratory syndrome s", "the mechanism resides in the inhibitory activity towards α-glucosidases that are involved in early stages of glycoprotein n-linked oligosaccharide processing in the endoplasmic reticulum, leading to a marked decrease of the viral spike protein.", "the iminosugar miglustat is a well-characterized drug for the treatment of rare genetic lysosome storage diseases such as gaucher and niemann-pick type c, and has also been described to be active against a variety of enveloped viruses.", 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  "the mechanism resides in the inhibitory activity towards -glucosidases that are involved in early stages of glycoprotein n-linked oligosaccharide processing in the endoplasmic reticulum, leading to a marked decrease of the viral spike protein.", "the activity of miglustat is here demonstrated for sars-cov-2 at concentrations achievable in the plasma by current clinical regimens without cytotoxicity.")